Cerebrospinal fluid Aβ42, tau, and F2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls

T. J. Montine, J. A. Kaye, K. S. Montine, L. McFarland, J. D. Morrow, J. F. Quinn

Research output: Contribution to journalArticle

96 Scopus citations

Abstract

Objective. - To test the hypothesis that quantification of cerebrospinal fluid (CSF) F2-isoprostanes (F2-IsoPs), in vivo biomarkers of free radical damage, along with CSF Aβ42 and tau levels improves laboratory diagnostic accuracy for Alzheimer disease (AD). Participants. - Patients with probable AD (n = 19), dementias other than AD (n = 8), and age-matched controls (n = 10). Main Outcome Measures. - Cerebrospinal fluid concentrations of Aβ42 and tau were determined by a commercially available test (Athena Diagnostics, Worcester, Mass). Cerebrospinal fluid F2-IsoP levels were quantified by gas chromatography/mass spectrometry. Results. - Individuals were classified as AD or non-AD by a published method using CSF Aβ42 and tau levels (95% sensitivity, 50% specificity), by CSF F2-IsoP levels greater than 25 pg/mL and Aβ42 concentrations less than 1125 pg/mL (90% sensitivity, 83% specificity), and by combined analysis using CSF F2-IsoP, Aβ42, and tau levels (84% sensitivity, 89% specificity). Conclusion. - Cerebrospinal fluid F2-IsoP quantification may enhance the accuracy of the laboratory diagnosis of AD.

Original languageEnglish (US)
Pages (from-to)510-512
Number of pages3
JournalArchives of Pathology and Laboratory Medicine
Volume125
Issue number4
StatePublished - Jan 1 2001

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Fingerprint Dive into the research topics of 'Cerebrospinal fluid Aβ<sub>42</sub>, tau, and F<sub>2</sub>-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls'. Together they form a unique fingerprint.

  • Cite this